
|Videos|March 10, 2015
Trial Designs in Ovarian Cancer
Author(s)Jason D. Wright, MD
Jason D. Wright, MD, from Columbia University, discusses clinical trial designs in ovarian cancer.
Advertisement
Clinical Pearls
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses clinical trial designs in ovarian cancer.
- Many patients with ovarian cancer receive a variety of off-label therapies. Nevertheless, overall survival has improved.
- The ovarian cancer community must weigh the pros and cons of a sound trial design with its application in the real world.
- Progression-free survival has its limitations but is probably the most reasonable trial endpoint.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5


















